Literature DB >> 1532592

Bilateral optic neuropathies with remission in two HIV-positive men.

N J Newman1, S Lessell.   

Abstract

Two patients seropositive for the human immunodeficiency virus (HIV) developed bilateral optic neuropathies. Evaluations failed to identify an infectious or neoplastic etiology. Both patients improved, one in temporal relation to treatment with azidothymidine (AZT), the other during oral steroid therapy. Optic neuropathy in HIV-positive patients does not necessarily carry a poor prognosis even when a treatable cause is not found. A role for primary HIV infection in the pathogenesis remains speculative.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1532592

Source DB:  PubMed          Journal:  J Clin Neuroophthalmol        ISSN: 0272-846X


  5 in total

1.  AIDS-related optic neuropathy: a histological, virological and ultrastructural study.

Authors:  A A Sadun; J S Pepose; M C Madigan; K A Laycock; W N Tenhula; W R Freeman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-07       Impact factor: 3.117

2.  Visual loss related to macular subretinal fluid and cystoid macular edema in HIV-related optic neuropathy.

Authors:  David Gautier; Valérie Rabier; Ghislaine Jallet; Dan Milea
Journal:  Int Ophthalmol       Date:  2012-05-13       Impact factor: 2.031

3.  Non-glaucomatous optic neuropathy in ibadan: extrapolations to healthcare funding in Nigeria.

Authors:  O A Ogun; O A Adediran
Journal:  Ann Ib Postgrad Med       Date:  2014-12

Review 4.  Infectious optic neuropathies: a clinical update.

Authors:  Rim Kahloun; Nesrine Abroug; Imen Ksiaa; Anis Mahmoud; Hatem Zeghidi; Sonia Zaouali; Moncef Khairallah
Journal:  Eye Brain       Date:  2015-09-28

5.  Vision recovery in human immunodeficiency virus-infected patients with optic neuropathy treated with highly active antiretroviral therapy: a case series.

Authors:  Kalpana Babu; Krishna R Murthy; Nirmala Rajagopalan; B Satish
Journal:  Indian J Ophthalmol       Date:  2009 Jul-Aug       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.